Circulation Research. 2002
Published online before print June 6, 2002, doi: 10.1161/01.RES.0000025268.10302.0C
Published online before print June 6, 2002, doi: 10.1161/01.RES.0000025268.10302.0C
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 18, 2002
Revised on May 2, 2002
Accepted on May 28, 2002
Osteopontin Plays an Important Role in the Development of Medial Thickening and Neointimal Formation
Kikuo Isoda *;
From First Department of Internal Medicine (K.I., K.N., Y.K., M.Y., M.K., F.O.), National Defense Medical College, Saitama; Third Department of Internal Medicine (M.M.), Toho University School of Medicine, Ohashi Hospital; and the Division of Biomedical Research Resources, Juntendo University School of Medicine (N.T.), Bunkyo-ku, Tokyo, Japan.
* To whom correspondence should be addressed. E-mail: isoda{at}me.ndmc.ac.jp.
Osteopontin (OPN) is a soluble secreted phosphoprotein that binds with high affinity to several integrins and it has been found at the site of atherosclerotic lesions. However, the role of OPN expression in vivo is still poorly understood. To investigate the physiological role of OPN in detail, we generated transgenic mice (Tg) overexpressing the OPN gene under control of the cytomegalovirus enhancer/chicken ß-actin promoter. We detected OPN mRNAs in almost all tissues of 3 lines of Tg mice by Northern blotting. The serum levels of OPN were significantly higher in Tg than in non-Tg mice (782±107 versus 182±44 ng/mL; P<0.001). Compared with non-Tg mice, a 73% (88±6 versus 51±7 µm; P<0.001) and 94% (126±15 versus 73±11 µm; P<0.0001) increase in the medial thickness of the aorta was determined in Tg mice at 16 and 32 weeks after birth. However, we found no evidence of inflammatory cells adhering to endothelial cells, intimal hyperplasia, or calcification in any region of Tg mice without artery injury. We then investigated the effect of cuff-induced injury to the femoral artery. The intimal thickening in Tg mice increased 2.9-fold more than that in non-Tg mice (4.9±1.9 versus 1.7±0.4 µm; P=0.022). The expression of OPN induces both medial thickening without injury and neointimal formation after injury, thus suggesting that OPN plays a role in the development of atherosclerosis, vascular remodeling, and restenosis after angioplasty in vivo.
Key words: aorta • atherosclerosis • genes • inflammation • smooth muscle
This article has been cited by other articles:
 |
|
 |
|
  M. Koshikawa, K. Aizawa, H. Kasai, A. Izawa, T. Tomita, S. Kumazaki, H. Tsutsui, J. Koyama, S. Shimodaira, M. Takahashi, et al. Elevated Osteopontin Levels in Patients With Peripheral Arterial Disease Angiology, February 1, 2009; 60(1): 42 - 45. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Eferl, P. Hasselblatt, M. Rath, H. Popper, R. Zenz, V. Komnenovic, M.-H. Idarraga, L. Kenner, and E. F. Wagner Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1 PNAS, July 29, 2008; 105(30): 10525 - 10530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-i. Miyazaki, Y. Okada, O. Yamanaka, A. Kitano, K. Ikeda, S. Kon, T. Uede, S. R. Rittling, D. T. Denhardt, W. W.-Y. Kao, et al. Corneal Wound Healing in an Osteopontin-Deficient Mouse Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1367 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Scatena, L. Liaw, and C. M. Giachelli Osteopontin: A Multifunctional Molecule Regulating Chronic Inflammation and Vascular Disease Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2302 - 2309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Miller, W. C. Watson, K. A. Kerr, C. A. Labarrere, N. X. Chen, M. A. Deeg, and J. L. Unthank Development of progressive aortic vasculopathy in a rat model of aging Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2634 - H2643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gomez-Ambrosi, V. Catalan, B. Ramirez, A. Rodriguez, I. Colina, C. Silva, F. Rotellar, C. Mugueta, M. J. Gil, J. A. Cienfuegos, et al. Plasma Osteopontin Levels and Expression in Adipose Tissue Are Increased in Obesity J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3719 - 3727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jalvy, M.-A. Renault, L. L. S. Leen, I. Belloc, J. Bonnet, A.-P. Gadeau, and C. Desgranges Autocrine expression of osteopontin contributes to PDGF-mediated arterial smooth muscle cell migration Cardiovasc Res, September 1, 2007; 75(4): 738 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Leali, E. Moroni, F. Bussolino, and M. Presta Osteopontin Overexpression Inhibits in Vitro Re-endothelialization via Integrin Engagement J. Biol. Chem., July 6, 2007; 282(27): 19676 - 19684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shaheen and N. L. Weintraub Osteopontin: A Bona Fide Mediator of Abdominal Aortic Aneurysm? Arterioscler Thromb Vasc Biol, March 1, 2007; 27(3): 439 - 441. [Full Text] [PDF]
|
|
|
|
 |
|
 C.-F. Lai, V. Seshadri, K. Huang, J.-S. Shao, J. Cai, R. Vattikuti, A. Schumacher, A. P. Loewy, D. T. Denhardt, S. R. Rittling, et al. An Osteopontin-NADPH Oxidase Signaling Cascade Promotes Pro-Matrix Metalloproteinase 9 Activation in Aortic Mesenchymal Cells Circ. Res., June 23, 2006; 98(12): 1479 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kato, Y. Momiyama, R. Ohmori, N. Tanaka, H. Taniguchi, K. Arakawa, M. Kusuhara, H. Nakamura, and F. Ohsuzu High Plasma Levels of Osteopontin in Patients With Restenosis After Percutaneous Coronary Intervention Arterioscler Thromb Vasc Biol, January 1, 2006; 26(1): e1 - e2. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsuki, K. Isoda, R. Horai, A. Nakajima, Y. Aizawa, K. Suzuki, F. Ohsuzu, and Y. Iwakura Involvement of Tumor Necrosis Factor-{alpha} in the Development of T Cell-Dependent Aortitis in Interleukin-1 Receptor Antagonist-Deficient Mice Circulation, August 30, 2005; 112(9): 1323 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Seipelt, C. L. Backer, C. Mavroudis, V. Stellmach, M. Cornwell, I. M. Seipelt, F. A. Schoendube, and S. E. Crawford Local delivery of osteopontin attenuates vascular remodeling by altering matrix metalloproteinase-2 in a rabbit model of aortic injury J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 355 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Seipelt, C. L. Backer, C. Mavroudis, V. Stellmach, M. Cornwell, I. M. Seipelt, F. A. Schoendube, and S. E. Crawford Osteopontin expression and adventitial angiogenesis induced by local vascular endothelial growth factor 165 reduces experimental aortic calcification J. Thorac. Cardiovasc. Surg., April 1, 2005; 129(4): 773 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Weisberg, F. Albornoz, J. P. Griffin, D. L. Crandall, H. Elokdah, A. B. Fogo, D. E. Vaughan, and N. J. Brown Pharmacological Inhibition and Genetic Deficiency of Plasminogen Activator Inhibitor-1 Attenuates Angiotensin II/Salt-Induced Aortic Remodeling Arterioscler Thromb Vasc Biol, February 1, 2005; 25(2): 365 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-A. Renault, S. Jalvy, M. Potier, I. Belloc, E. Genot, L. V. Dekker, C. Desgranges, and A.-P. Gadeau UTP Induces Osteopontin Expression through a Coordinate Action of NF{kappa}B, Activator Protein-1, and Upstream Stimulatory Factor in Arterial Smooth Muscle Cells J. Biol. Chem., January 28, 2005; 280(4): 2708 - 2713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Giacopelli, R. Marciano, A. Pistorio, P. Catarsi, S. Canini, G. Karsenty, and R. Ravazzolo Polymorphisms in the osteopontin promoter affect its transcriptional activity Physiol Genomics, December 15, 2004; 20(1): 87 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sahai, P. Malladi, X. Pan, R. Paul, H. Melin-Aldana, R. M. Green, and P. F. Whitington Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin Am J Physiol Gastrointest Liver Physiol, November 1, 2004; 287(5): G1035 - G1043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Abe, K. Hiura, J. Wilde, A. Shioyasono, K. Moriyama, T. Hashimoto, S. Kido, T. Oshima, H. Shibata, S. Ozaki, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion Blood, October 15, 2004; 104(8): 2484 - 2491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sahai, P. Malladi, H. Melin-Aldana, R. M. Green, and P. F. Whitington Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model Am J Physiol Gastrointest Liver Physiol, July 1, 2004; 287(1): G264 - G273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Berman, D. Serlin, X. Li, G. Whitley, J. Hayes, D. C. Rishikof, D. A. Ricupero, L. Liaw, M. Goetschkes, and A. W. O'Regan Altered bleomycin-induced lung fibrosis in osteopontin-deficient mice Am J Physiol Lung Cell Mol Physiol, June 1, 2004; 286(6): L1311 - L1318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Vattikuti and D. A. Towler Osteogenic regulation of vascular calcification: an early perspective Am J Physiol Endocrinol Metab, May 1, 2004; 286(5): E686 - E696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-S. Shao, S.-L. Cheng, N. Charlton-Kachigian, A. P. Loewy, and D. A. Towler Teriparatide (Human Parathyroid Hormone (1-34)) Inhibits Osteogenic Vascular Calcification in Diabetic Low Density Lipoprotein Receptor-deficient Mice J. Biol. Chem., December 12, 2003; 278(50): 50195 - 50202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-L. Chang, M. Cao, and P. Hicks Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells Carcinogenesis, November 1, 2003; 24(11): 1749 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Isoda, M. Shiigai, N. Ishigami, T. Matsuki, R. Horai, K. Nishikawa, M. Kusuhara, Y. Nishida, Y. Iwakura, and F. Ohsuzu Deficiency of Interleukin-1 Receptor Antagonist Promotes Neointimal Formation After Injury Circulation, August 5, 2003; 108(5): 516 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Myers, K. J. Harmon, V. Lindner, and L. Liaw Alterations of Arterial Physiology in Osteopontin-Null Mice Arterioscler Thromb Vasc Biol, June 1, 2003; 23(6): 1021 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Matsui, S. R. Rittling, H. Okamoto, M. Inobe, N. Jia, T. Shimizu, M. Akino, T. Sugawara, J. Morimoto, C. Kimura, et al. Osteopontin Deficiency Attenuates Atherosclerosis in Female Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, June 1, 2003; 23(6): 1029 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Isoda, Y. Kamezawa, M. Ayaori, M. Kusuhara, N. Tada, and F. Ohsuzu Osteopontin Transgenic Mice Fed a High-Cholesterol Diet Develop Early Fatty-Streak Lesions Circulation, February 11, 2003; 107(5): 679 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. de Waard, T. A.E. van Achterberg, N. J. Beauchamp, H. Pannekoek, and C. J.M. de Vries Cardiac Ankyrin Repeat Protein (CARP) Expression in Human and Murine Atherosclerotic Lesions: Activin Induces Carp in Smooth Muscle Cells Arterioscler Thromb Vasc Biol, January 1, 2003; 23(1): 64 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bidder, J.-S. Shao, N. Charlton-Kachigian, A. P. Loewy, C. F. Semenkovich, and D. A. Towler Osteopontin Transcription in Aortic Vascular Smooth Muscle Cells Is Controlled by Glucose-regulated Upstream Stimulatory Factor and Activator Protein-1 Activities J. Biol. Chem., November 8, 2002; 277(46): 44485 - 44496. [Abstract] [Full Text] [PDF]
|
|